Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB-001 for Recurrent Herpes Labialis
NCT01695187Phase 3Unknown
- Sponsor
- BlueWillow Biologics
- Start
- Oct 2012
- Primary completion
- Jun 2013
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in herpes labialis comparing NB-001 (0.3%) with Vehicle (2 arms). Primary endpoint: Time to healing of the primary lesion complex at 16 days. Status: unknown.
02
Drugs
NB-001
03
Conditions
herpes labialis
Beyond the preview
Go deeper on NCT01695187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695187.